Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

Background Blockade of the lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atherosclerosis. This study aims to assess the safety, tolerability, and target engagement of MEDI6570, a high‐af...

Full description

Bibliographic Details
Main Authors: Andrea L. Vavere, Marvin Sinsakul, Emily L. Ongstad, Ye Yang, Vijayalakshmi Varma, Christopher Jones, Joanne Goodman, Vincent F. S. Dubois, Angelica L. Quartino, Sotirios K. Karathanasis, Liron Abuhatzira, Anna Collén, Charalambos Antoniades, Michael J. Koren, Ruchi Gupta, Richard T. George
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
atherosclerosis
cardiovascular disease
coronary CTA
diabetes
LOX‐1
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.027540

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.027540

Similar Items